-
Product Insights
IgA Nephropathy (Berger’s Disease) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
IgA Nephropathy Clinical Trial Report Overview A total of 298 IgA Nephropathy clinical trials were conducted as of January 2024. The IgA Nephropathy clinical trial report provides a comprehensive understanding of the IgA Nephropathy clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions ·       Asia-Pacific ·       Europe...
-
Product Insights
Acute Renal Failure (ARF) (Acute Kidney Injury) – Drugs In Development, 2023
Global Markets Direct’s, ‘Acute Renal Failure (ARF) (Acute Kidney Injury) - Drugs In Development, 2023’, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
IgA Nephropathy (Berger’s Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘IgA Nephropathy (Berger's Disease) - Drugs In Development, 2023’, provides an overview of the IgA Nephropathy (Berger's Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for IgA Nephropathy (Berger's Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Kidney Fibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Kidney Fibrosis - Drugs In Development, 2023’, provides an overview of the Kidney Fibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Kidney Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Membranous Glomerulonephritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Membranous Glomerulonephritis - Drugs In Development, 2023’, provides an overview of the Membranous Glomerulonephritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Membranous Glomerulonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Drugs In Development, 2023
Global Markets Direct’s, ‘End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Drugs In Development, 2023’, provides an overview of the End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Nephrotic Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Nephrotic Syndrome - Drugs In Development, 2023’, provides an overview of the Nephrotic Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Nephrotic Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease) - Drugs In Development, 2023’, provides an overview of the Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis) – Drugs In Development, 2023
Global Markets Direct’s, ‘Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis) - Drugs In Development, 2023’, provides an overview of the Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Chronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Kidney Disease (Chronic Renal Failure) - Drugs In Development, 2023’, provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...